Taking into account that thrombosis is the main cause of morbidity and mortality in patients with JAK2 V617 MPN, the clinically relevant cut-off level of JAK2 mutation burden to start prophylactic anticoagulation remains to be determined, i.e., >0% vs. ≥2%. This evidence concerns the gene JAK2 and myeloproliferative disorder.